Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis

Michael B. Donald, Kevin X. Rodriguez, Hannah Shay, Puay Wah Phuan, A. S. Verkman, Mark J. Kurth

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Copper catalyzed azide-alkyne cycloaddition (CuAAC) chemistry is reported for the construction of previously unknown 5-(1H-1,2,3-triazol-1-yl)-4,5′- bithiazoles from 2-bromo-1-(thiazol-5-yl)ethanones. These novel triazolobithiazoles are shown to have cystic fibrosis (CF) corrector activity and, compared to the benchmark bithiazole CF corrector corr-4a, improved log P values (4.5 vs 5.96).

Original languageEnglish (US)
Pages (from-to)5247-5253
Number of pages7
JournalBioorganic and Medicinal Chemistry
Issue number17
StatePublished - Sep 1 2012


  • CF corrector
  • CuAAC
  • Cystic fibrosis
  • Triazolobithiazole

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry


Dive into the research topics of 'Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis'. Together they form a unique fingerprint.

Cite this